Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19

Inclusion Criteria: * Age 18 years or above * Written informed consent from the trial subject has been obtained * Willing to follow contraception guidelines * Tested positive for SARS-CoV-2 by PCR \<72 hours after swab * A maximum of 14 days between onset of symptoms and enrollment * WHO score 5 OR * WHO score 4 with at least one additional risk factor for disease progression * Acceptable risk factors are: * Radiographically proven lung infiltrates * Immunosuppression either by malignant disease or it's treatment, or other underlying diseases leading to immunodeficiency or underlying diseases that require treatment resulting in immunosuppression * Immunosuppressive drugs or steroids at a prednisolone equivalent of \<1 mg/kg BW) * Receipt of an autologous transplant within the last 5 years * Receipt of an allogeneic transplant within the last 5 years or ongoing immunosuppression Exclusion criteria: * Participation in any other clinical trial of an experimental agent treatment * Active GvHD or history of GvHD * History of CAR-T-Cell Therapy * COVID-19 WHO ordinal scale ≥6 * Anticipated life-expectancy \<72 hours * Expected duration of hospital stay \<72 hours * Sepsis-induced leukopenia or thrombocytopenia (leukocytes \<1,000/µl or platelets \<50,000/µl). If the cytopenias result from underlying hematologic disease or its treatment this will not be regarded as exclusion criterion * CT pneumonia score ≥13 \[50\] * Any Steroids ≥1 mg/kg Prednisolon-equivalent/kg BW, besides 6 mg Dexamethasone i.v. or p.o. 1x/d as SoC for COVID-19 * Pregnant or breast feeding * Any serious medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the subject's safe participation in and completion of the study * Therapeutic donor lymphocyte infusion (DLI) less than 100 days prior to IMP infusion * Known hypersensitivity to iron dextran * Known pre-existing human anti-mouse antibodies (HAMAs) * ontraindication against mandatory protocol-inherent comedication(s): antihistamine and/or acetaminophen * Failure to use highly-effective contraceptive methods. The following contraceptive methods with a Pearl Index lower than 1% are regarded as highly-effective: * Oral hormonal contraception ('pill') * Dermal hormonal contraception * Vaginal hormonal contraception (NuvaRing®) * Contraceptive plaster * Long-acting injectable contraceptives * Implants that release progesterone (Implanon®) * Tubal ligation (female sterilization) * Intrauterine devices that release hormones (hormone spiral) * Double barrier methods * This means that the following are not regarded as safe: condom plus spermicide, simple barrier methods (vaginal pessaries, condom, female condoms), copper spirals, the rhythm method, basal temperature method, and the withdrawal method (coitus interruptus). * Persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator * Legally incapacitated persons * Persons held in an institution by legal or official order